Theratechnologies Inc T.TH

RE:RE:RE:RE:RE:Institutional investor buying

[qwerty22]

Yes and you just posted a news report about Taimed from a website that seems to suggest Taimed has 18,000 follower there. What is that doing for Taimed's stock price?

Sesen is on a roll because people see an approval coming. Thtx was on a roll when people could see Trogarzo approval coming. They will be on a roll again if they get a story that excites people. Honestly outside of us schmucks you can't excite with an oncology program with no clinical data and a NASH program that has never had a company run trial and doesn't have one planned any time soon.

Paul wants to avoid a release where n=1 but let's be honest it could be as bad as that. Galectin essentially had an n=1 responder on their dose escalation PR. People are looking for ballpark on where this lands. It can be anywhere from bad to meh to really great.

I'm going to end up with a bag of Cheetos courtesy of Wino because I'm essentially like Ed Nash. He prioritizes getting clarity before jumping in and I can appreciate that sentiment. I think the next cancer data is potentially big but I don't think it's necessarily data you get in ahead of. I think, if it's OK or better then it's data you start accumulating from.

If you want a push toward retail then do it with shrinking human tumour data.

scarlet1967 wrote:

I get it, they want to bring institutions onboard which is great but nothing on retail front when almost 60% of trading is done by retail investors doesn't make sense. Sesen for instance has about 37k followers on Stocktwits, multiple posts every minute now worth over  $1.1 B. Looking at their website they have monthly business updates. So why not approaching that opportunity at all? 

https://ir.sesenbio.com/events-and-presentations
 

SPCEO1 wrote: I don't think that $3.87 price is the price they bought at. I suspect it is the price at the end of June which is date of when the filing was due.

It is nice to see a little buying by institutions but it is quite tiny. And that is to be expected since the market cap of the stock is so small and the share price is below $5 per share. Both are huge limitations to institutional buying.

Yet as far as we can tell, TH is persisting in targeting its investor relations efforts towards institutions who cannot actually buy much, if any in most cases, of its shares.

Furthermore, TH has substandard analyst coverage, but again, with such a small market cap and no need for immediate financing, the brokers have no incentive to cover the stock, or cover it well. Indicative of that substandard coverage, none of the four brokers covering TH have written a report on today's news (it is possible they have mentioned it in some internal notes). 

Moreover, TH's IR person is on vacation this week so responding to incoming inquiries about the news today is not likely happening.

We own a small company's stock and by virtue of the sub-$5 share price and the its previous unsuccessful drug commercializations and mis-guided IR efforts, the stock price is well below what we could reasonably expect it to be in the current market conditions. Hopefully, with actual safety and preliminary efficacy data on the near term horizon, we will see the stock move above $5 per share and then later above $1 billion in market cap. At such time, it should be much easier, though still not easy because a $1 billion market cap stock is still too tiny for many institutions to buy, to have the share price more fairly reflect the company's prospects.
 

 

scarlet1967 wrote: Last time the price was at $3.87 was more than a month ago. The sellers again are unmotivated retail investors. So longtime shareholders paying the price because the company is reluctant so far to address this ongoing issue.

Bucknelly21 wrote: So institutes adding but someone is selling at the same time.... price is stagnant